javabuckeye.com

Galapagos Receives EUR 4 M Milestone for First Clinical Trial in GlaxoSmithKline Alliance

Market Wire, December, 2009

* First program from GSK arthritis alliance to reach clinic
* Based on kinase target identified through Galapagos'
  target discovery platform
* Galapagos receives EUR 4 M milestone payment from GSK

Galapagos NV (Euronext: GLPG)
announced today that it has initiated clinical Phase I development of
the first small molecule candidate from its arthritis alliance with
GlaxoSmithKline (GSK). For entering the clinic with candidate drug
GLPG0555, Galapagos receives a milestone payment of EUR 4 million cash
from GSK. Since the start of the arthritis alliance in June 2006,
Galapagos has received a total of EUR 35 million in payments from GSK.

The orally-available, novel candidate drug GLPG0555 modifies kinase
target GT622 and was identified through Galapagos’ proprietary target
discovery platform. Candidate drug GLPG0555 has demonstrated
excellent activity in biochemical and animal models and has
successfully completed pre-clinical development.

“This alliance with GSK was Galapagos’ first, adding a special
significance to today’s clinical milestone. By funding an alliance
program from target discovery to Phase I through success-based
payments, we are achieving what we set out to do with our alliance
strategy. This trial marks the first of what we would hope to be
many programs from the arthritis alliance with GSK to enter the
clinic,” said Onno van de Stolpe, Chief Executive Officer of
Galapagos.

With the initiation of the Phase I trial with GLPG0555, Galapagos now
has four candidate drugs in clinical development (Phase I and Phase
II).

Details of the Phase I clinical trial

The primary endpoints of this first-in-human trial will be to
determine the safety, tolerability, and pharmacokinetics of the
candidate drug GLPG0555. The double blind, single ascending and
multiple dose studies will be conducted in 34 healthy human
volunteers in Belgium over the coming months.

About Galapagos’ arthritis alliance with GlaxoSmithKline

GSK and Galapagos initiated an arthritis alliance to discover and
develop disease-modifying drugs for GSK’s global R&D; organization in
June 2006
rituxan rheumatoid arthritis

Been in search of a brand new Maryland auto insurance quote? If you found the least expensive one there is you won’t look any further? However, that usually isn’t the best decision that you can make.

The truth is, all of us would really like to find the top Maryland auto insurance quote offered. In addition, a second major consideration is that we want to see that the insurance we get will be worth it. Make sure that you understand what is essential to get the quality insurance that you deserve.

Start by shopping for quotes and have minimum three Maryland car insurance quotes to review. The simplest method will be to look online because insurance companies will compete for your business and give you fast and affordable quotes within a few minutes. At least 73% of insurance shoppers look online for fast and free insurance quotes.

Afteryou have gotten no less than 3 MD auto insurance quotes, your next step is to see that your insurance company will be helpful and assist you should you have to make a claim. Give a call their customer care center and see if they can help and answer the questions you ask. It’s this group that you have to face when making claims or calling with questions
sr22 maryland

PTC Therapeutics Receives $1 Million Challenge Grant Award from the National Institutes of Health

PR Newswire, Dec 2, 2009

– Funding supports continued focus on rare disorders -

SOUTH PLAINFIELD, N.J., Dec. 2 /PRNewswire/ — PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million Challenge Grant award from the National Heart, Lung, and Blood Institute (NHLBI) as part of the National Institutes of Health (NIH). According to the NIH, 840 grants were awarded out of the approximately 20,000 applications they received for the Challenge Grants, a new program under the American Recovery and Reinvestment Act designed to stimulate new areas of research. This was the largest response to a grant in NIH’s history. The two-year grant will support an ongoing Phase 2a clinical trial of ataluren in hemophilia A and B due to a nonsense mutation.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

“We are honored to receive this grant from the NIH,” said Stuart W. Peltz, Ph.D., president and Chief Executive Officer of PTC Therapeutics. “A majority of the grants were awarded to academic institutions, non-profits and hospitals and we are proud to be one of the few corporations to receive funding. This grant supports our continued commitment to developing innovative therapies for patients with serious and life threatening conditions.”

Patients with hemophilia, a rare and debilitating genetic disorder, have a loss of blood clotting proteins, which can lead to serious, recurrent bleeding episodes. Current therapies require repeated, frequent intravenous infusions to maintain their protein levels. PTC recently announced the initiation of the Phase 2a clinical trial of ataluren, an oral investigational new drug, in adult male patients with nonsense mutation hemophilia A and nonsense mutation hemophilia B. Approximately 10 to 30 percent of patients with hemophilia have the disease due to a nonsense mutation. More information regarding hemophilia is available through the National Hemophilia Foundation (http://www.hemophilia.org/) and through the NHLBI (http://www.nhlbi.nih.gov/health/dci/Diseases/hemophilia/hemophilia_what.html) . Additional information on the clinical trial can be found on clinicaltrials.gov (NCT00947193 or keywords: ataluren and hemophilia).

About Challenge Grants

The American Recovery and Reinvestment Act (ARRA) of 2009 makes supplemental appropriations for job preservation and creation, infrastructure investment, energy efficiency and science, assistance to the unemployed and State and local fiscal stabilization. Through the ARRA, NIH awarded $389,161,204 to 840 projects for the Challenge Grants Program in Health and Science Research. This new program is designed to spur new areas of research and supports research on Challenge Topics, which address specific scientific and health research challenges in biomedical and behavioral research that will benefit from significant two-year jumpstart funds. Challenge Areas, defined by the NIH, focus on specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that would benefit from an influx of funds. The research in these areas should have a high impact in biomedical or behavioral science and/or public health. The grant is supported by Award Number RC1HL100159 from the NIH’s National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute.

About PTC Therapeutics

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of oral drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC’s internally discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology, and infectious diseases
signs of rheumatoid arthritis

Morph Labs Announces Private Cloud Trial Kit

Market Wire, December, 2009

Morph Labs, a leading provider of
enterprise cloud computing technology, today announced an introductory
trial of the Morph CloudServer ( www.g2ix.com/cloudserver ), an open,
standards-based server IT organizations can use to rapidly model and
evaluate their cloud implementations.

A miniature “Cloud Environment in a Box,” the system will include the Morph
Cloud Controller, a complete cloud management and provisioning platform
that leverages the Amazon AWS API, and a Virtual Machine Server
pre-configured with 10 VMs. Evaluators who require a bigger environment can
add a VM server, as needed. Morph Labs also offers an option for a fully
hosted starter kit trial.

“Our goal is to simplify and accelerate the adoption of cloud computing by
placing actual technology into the evaluators’ hands,” says Winston
Damarillo, CEO of Morph Labs. “The Morph CloudServer starter kits are
optimized to provide IT organizations with a secure way to test their model
implementations based on Open Standard cloud environments.”

Cloud computing is rapidly gaining widespread global adoption
hard drive rescue

First Delivery of I-TESS to U.S. Marine Corps Base Quantico for Instrumented-Tactical Engagement Simulation System (I-TESS) by Saab Training USA

Market Wire, December, 2009

Saab Training USA, a business unit of Saab
(STKM: SAAB.B), announced that it has delivered its first set of
Instrumented – Tactical Engagement Simulation System (I-TESS) at the U.S.
Marine Corps Base Quantico — within 6 month of contract award. This
represents the first fielding of I-TESS under a $28.8 million contract
awarded to Saab Training USA by the U.S. Marine Corps Systems Command,
Orlando, Florida. Development and production will take place in Orlando,
Florida and the expected completion date is April 2011.

I-TESS is a member of Saab’s Deployable Instrumented Training Systems
(DITS) family of live training products that is used by militaries and
security professionals throughout the world. I-TESS is a modular and
mobile integrated instrumentation system that provides laser-based
force-on-force training with Position Location Information (PLI) reporting,
battle tracking, data collection and rapid After-Action Reviews (AARs) for
live training events. I-TESS offers real-time situational awareness,
exercise control capabilities, and adjudication of direct and indirect fire
engagements to help facilitate the training exercise objectives. The
I-TESS system will be used in Military Operations in Urban Terrain (MOUT)
facilities and non-live fire maneuver areas located at various U.S. Marine
Corp bases and installations. I-TESS supports the USMC Pre-deployment
Training Program (PTP) and other Individual through Regimental Combat
Team-level training exercises.

“I-TESS will significantly expand the current base of instrumentation
systems already fielded by Saab for the U.S. Marine Corps,” says Lars
Borgwing, President, Saab Training USA. “In addition to underscoring
Saab’s position as a leader in the U.S. simulation training industry, this
new contract expands our global footprint as the same instrumentation
system is fielded with the U.S. Army, U.S. Navy SEALs and five major armies
in Europe.”

Ken Polczynski, Saab’s USMC Program Manager, adds: “The I-TESS program will
immediately provide the Marine Corps the ability to train anywhere at any
time without changing infrastructure. United States Marines are highly
skilled at facing dangerous situations every day, and now they have the
ability to hone those battle skills more quickly and effectively.”

About Saab Training USA

Saab Training USA is located in the Orlando Central Florida’s Research Park
and has supported the U.S
business training sydney

Cash boost for village pool

0 Comments | Hemel Gazette (Hemel Hempstead, England), Dec 1, 2009

A major refurbishment project has recently been completed at Kings Langley Secondary School and further improvements are in the pipeline thanks to a cash injection from Herts County Council.

Cllr Richard Roberts, who represents the village at county, dipped into his locality budget to award the Love Lane school A[pounds sterling]1,700 to promote health and fitness.

The money will be used to boost decor, changing rooms, benches and showers at the facility – that is also used by primary school children, swimming clubs and village residents.

Next year’s revamped KidFest in Concord to be smaller

0 Comments | Oakland Tribune, Dec 3, 2009 | by Paul Thissen

Concord will hold on to the KidFest name, and the event will still draw children to Todos Santos Plaza for games, rides and excitement.

But little else will be the same.

Rather than a three-day event over Memorial Day weekend, KidFest will be a one-day affair on Father’s Day.

And rather than surrounding the plaza with a fence and charging a fee to enter, the event will be a smaller addition to an existing Father’s Day celebration that already was scheduled to include live music and a chili cook-off between area fire departments.

The changes come because the 20-year-old event’s longtime organizer said earlier this year that he would not produce another one. For a while, it appeared KidFest was dead.

Then, event organizer Jay Bedecarre said he wanted to continue it — but not next year, not on Memorial Day, and not at Todos Santos Plaza.

Hie is organizing a children’s event for the upcoming Memorial Day weekend that will include most of the rides and vendors of the 2009 KidFest — but it will be at Heather Farm Park in Walnut Creek.

Concord City Councilman Mark Peterson was not happy at the prospect of a year off from KidFest, so he had asked city staff members to look into other ways to host the event.

The Todos Santos Business Association was not interested in helping with any event on Memorial Day that would compete with the Walnut Creek event, according to a city staff report.

However, they were interested in holding a smaller, one-day event on Father’s Day along with the chili cook-off. Those events come the day after a big Corvette show at the plaza.

Police and public works staff members already would be on-call for the existing events, so it would be easier and less expensive to plan, according to Florence Weiss, Concord’s downtown program coordinator.

She will work with the business association to plan the new KidFest based on the decision at the City Council committee meeting, which included Peterson, Councilman Bill Shinn, Weiss and Virginia Thomas, president of the board of directors of the Todos Santos Business Association.

Peterson said he liked the idea of holding the children’s event on Father’s Day.

Shinn agreed, saying to Peterson: “If you’re happy, pal, I’m tickled.”

Reach Paul Thissen at 925-943-8163.

Scandal suspect on the run from mafia: lawyer

0 Comments | AFP, December, 2009

BERLIN (AFP) The captain of regional German side SC Verl, suspended under suspicion of being involved in Europe’s betting scandal, has gone into hiding through fear of mafia retribution, his lawyer said on Tuesday.

Midfielder Patrick Neumann was last week suspended by his club, based near Bielefeld which plays in the Regionalliga West, and is now in hiding through fear of figures involved in the betting scandal, said his lawyer Lutz Klose.

“Patrick is very afraid and panicking,” said Klose.

“He can identify the contact people involved.

“He is worried this time they will use not cunning and bribery, but intimidation and force.”

According to Klose, Neumann had been offered between 5,000 to 10,000 euros (7,500-15,000 US dollars) if his side lost a…

140 jets, 1,200 limos, 15,000 officials 98 leaders.. 1 chance to

0 Comments | Daily Mirror, The; London (UK), Dec 7, 2009 | by DAMIEN FLETCHER

IT’S billed as the last chance to save the Earth but the climate change summit will burn a lot of hot air before there’s any deal.

Delegates from 192 countries gather today for 12 days of talks on cutting greenhouse gasses.

But the summit will generate 40,500 tons of CO2 – roughly equal to what Middlesbrough will produce in the same period
limo hire manchester

Immediate strength boost: quench your thirst to boost your strength by 10%

Flex, Jan, 2010 by Greg Merritt, Jim Stoppani

HYPOTHESIS Staying hydrated is important not only for health reasons and for keeping your muscles full, but also for muscle strength.

RESEARCH Several clinical studies have looked into the effects of dehydration on muscle strength. One study performed at Old Dominion University (Virginia) tested weight-trained men’s bench press one-rep max when they were normally hydrated versus when they were dehydrated. A University of Connecticut (Storrs) study compared the total number of reps that weight-trained men completed during six sets of squats using 80% of their 1RM when they were either normally hydrated or dehydrated. And a 2008 study by Chicago State University researchers tested the muscle power of subjects when they were normally hydrated and when they were dehydrated.

FINDINGS The Old Dominion study found that when the subjects were dehydrated, their 1RM was about 10% less than when they were normally hydrated. They also found that the leaner the subjects were, the more that dehydration reduced their strength. The UConn scientists reported that when the subjects were dehydrated, they completed fewer reps on the squat during most of the 6 sets than they did when they were normally hydrated. The Chicago State researchers found that when the subjects were dehydrated, their muscle power was reduced by about 20% compared to when they were normally hydrated.

CONCLUSION If you don’t drink enough fluids, you could run the risk of having less muscle strength, power and endurance. All of this could have a negative impact on your muscle growth.

APPLICATION Most bodybuilders think that dehydration is something that only marathon runners need to worry about. Not so. The research showing that dehydration decreased strength by 10% was done with subjects losing just 1.5% of their bodyweight. That’s just over 2 pounds of body weight for a 180-pound guy. Does your weight fluctuate from day to day by a couple of pounds? You’d better believe it. And when it’s down by just that little amount, your strength may drop by as much as 10%. Think of it this way: staying well hydrated could increase your strength immediately by 10%! To stay hydrated, drink about 1 gallon of water per day.

–Jim Stoppani, PhD

References: J.E
schwinn 418 elliptical trainer